Prevention of Acute Rejection and Allograft Vasculopathy by Everolimus in Cardiac Transplants Recipients: A 24-Month Analysis

Journal of Heart and Lung Transplantation

Volumn 26, Issue 6, 2007, Pages 584-592

  Viganò, Mario ^a   Tuzcu, Murat ^b   Benza, Raymond ^c   Boissonnat, Pascale ^d   Haverich, Axel ^e   Hill, James ^f   Laufer, Guenther ^g   Love, Robert ^h   Parameshwar, Jayan ⁱ   Pulpón, Luis Alonso ^j   Renlund, Dale ^k   Abeywickrama, Kamal ^l   Cretin, Nathalie ^l   Starling, Randall C ^b   Eisen, Howard J ^m  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d LOUIS PRADEL HOSPITAL   (France)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY OF FLORIDA   (United States)

^g Universitatsklinik fur Chirurgie Innsbruck   (Austria)

^h University of Wisconsin Health   (United States)

ⁱ PAPWORTH HOSPITAL   (United Kingdom)

^j HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^k UNIVERSITY OF UTAH   (United States)

^l NOVARTIS PHARMA AG   (Switzerland)

^m DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; OKT 3; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; INFECTION SENSITIVITY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AZATHIOPRINE; CYCLOSPORINE; DOUBLE-BLIND METHOD; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; MIDDLE AGED; SAFETY; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 34249279808     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.03.005     Document Type: Article

References (30)

1. Young J.B. Allograft vasculopathy: diagnosing the nemesis of heart transplantation. Circulation 100 (1999) 458-460
2. Weiss M., and von Scheidt W. Cardiac allograft vasculopathy: a review. Circulation 96 (1997) 2069-2077
3. Young J.B. Perspectives on cardiac allograft vasculopathy. Curr Atheroscler Rep 2 (2000) 259-271
4. Kapadia S., Nissen S., and Tuzcu M. Impact of intravascular ultrasound in understanding transplant coronary artery disease. Curr Opin Cardiol 14 (1999) 140-150
5. Kobashigawa J.A. First-year intravascular ultrasound results as a surrogate marker for outcomes after heart transplantation. J Heart Lung Transplant 22 (2003) 711-714
6. Kobashigawa J.A., Tobis J.M., Starling R.C., et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 45 (2005) 1532-1537
7. Tuzcu E.M., Kapadia S.R., Sachar R., et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 45 (2005) 1538-1542
8. Dumont F.J. Treatment of transplant rejection: are the traditional immunosuppressants good enough?. Curr Opin Invest Drugs 2 (2001) 357-363
9. Cole O.J., Shehata M., and Rigg K.M. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 30 (1998) 2200-2203
10. Schuurman H.J., Pally C., Weckbecker G., Schuler W., and Bruns C. SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc 31 (1999) 1024-1025
11. Nishimura T., Faul J., Berry G.J., Veve I., Pearl R., and Kao P.N. 40-0-(2-hydroxylethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Resp Crit Care Med 163 (2001) 498-502
12. Schuler W., Sedrani R., Cottens S., et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64 (1997) 36-42
13. Schuurman H.J., Cottens S., Fuchs S., et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 64 (1997) 32-35
14. Hausen B., Boeke K., Berry G., Segarra I.T., Christians U., and Morris R.E. Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J Heart Lung Transplant 18 (1999) 150-159
15. Eisen H.J., Tuzcu M., Dorent R., et al. Everolimus for the prevention of allograft and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (2003) 847-858
16. Nashan B., Curtis J., Ponticelli C., et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 78 (2004) 1332-1340
17. Vitko S., Tedesco H., Eris J., et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 4 (2004) 626-635
18. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75 (1988) 800-802
19. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 53 (1958) 457-481
20. Valantine H. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican phase III clinical trial. J Heart Lung Transplant 24 suppl 4 (2005) S191-S195
21. Valantine H., and Zuckermann A. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation. J Heart Lung Transplant 24 suppl 4 (2005) S185-S190
22. Keogh A. Long-term benefits of mycophenolate mofetil after heart transplantation. Transplantation 79 suppl (2005) S45-S46
23. Mehra M., Ventura H., Stapleton D., Smart F., Collins T., and Ramee S. Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. J Heart Lung Transplant 14 (1995) 632-639
24. Rickenbacher P., Pinto F., Lewis N., et al. Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation. Circulation 92 (1995) 3445-3452
25. Liang D., Gao S., Botas J., Pinto F.J., Schroeder J.S., Alderman E.L., and Yeung A.C. Prediction of angiographic disease by intracoronary ultrasonographic findings in heart transplant recipients. J Heart Lung Transplant 15 (1996) 980-987
26. Kobashigawa JA, Tobis JM, Mentzer RM, et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant 1006;6:993-7.
27. Lehmkuhl H., and Hetzer R. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum, Berlin. J Heart Lung Transplant 24 suppl 4 (2005) 201-205
28. Hummel M. Recommendations for the use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference. J Heart Lung Transplant 24 suppl 4 (2005) 196-200
29. Zuckermann A. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna. J Heart Lung Transplant 24 suppl 4 (2005) 206-209
30. Kovarik J.M., Kaplan B., Tedesco Silva H., et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 73 (2002) 920-925